STOCK TITAN
  1. Home
  2. News
  3. NMTC

NeuroOne Medical Technologies Corporation - NMTC STOCK NEWS

Welcome to our dedicated page for NeuroOne Medical Technologies Corporation news (Ticker: NMTC), a resource for investors and traders seeking the latest updates and insights on NeuroOne Medical Technologies Corporation stock.

NeuroOne Medical Technologies Corporation (symbol: NMTC) is a cutting-edge medical technology company based in Eden Prairie, Minnesota. The company specializes in the development and commercialization of innovative thin-film electrode technology designed for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, brain stimulation, and ablation solutions. These technologies are particularly beneficial for patients suffering from a variety of brain-related disorders, including epilepsy, Parkinson's disease, dystonia, and essential tremors.

NeuroOne's core business revolves around creating comprehensive neuromodulation solutions that integrate cEEG and sEEG recording, monitoring, brain stimulation, and ablation. This focus has led to notable advancements such as the Evo® sEEG system, which is the first FDA-cleared thin-film sEEG-guided RF system capable of both recording electrical activity and ablating nervous tissue, with the added benefit of temperature control.

The company is actively involved in various exciting projects and partnerships. One of their key initiatives is the Drug Delivery Program, which is expected to achieve several important milestones in the near future. Additionally, NeuroOne is continuously enhancing its product portfolio to better serve its target patient population.

Financially, NeuroOne has provided promising updates for the second quarter of the fiscal year 2024. The company’s recent business highlights include significant progress in their OneRF™ Ablation System and Spinal Cord Stimulation Program. Investors and interested parties can access more detailed financial results and updates through their quarterly conference calls and webcasts.

For more information or to get in touch with NeuroOne, please contact them at 800-631-4030 or email ir@nmtc1.com.

News

NeuroOne® to Report First Quarter Fiscal Year 2024 Financial Results and Provide Corporate Update on February 13

Rhea-AI Summary
NeuroOne Medical Technologies Corporation (NMTC) will host a conference call and webcast on February 13, 2024, to discuss its financial results for the first quarter of fiscal year 2024 and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
conferences earnings
-
News

NeuroOne® Reports Fiscal Fourth Quarter and Full Fiscal Year 2023 Financial Results and Provides Corporate Update

Rhea-AI Summary
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) announces fiscal fourth quarter and full fiscal year ended September 30, 2023 results. Q4 2023 product revenue of $742,000, up from $69,000 in Q4 2022. Full-year product revenue of $1,952,000, up from $171,000 in FY 2022. Completed $6M capital raise in July 2023. FDA clearance for OneRF Ablation System in December 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.05%
Tags
earnings
-
News

NeuroOne® Receives FDA 510(k) Clearance to Market its OneRF™ Ablation System

Rhea-AI Summary
NeuroOne Medical Technologies Corporation (NMTC) receives FDA 510(k) clearance for its OneRF Ablation System, the first FDA-cleared thin-film, sEEG-guided RF system capable of recording electrical activity and ablating nervous tissue with temperature control. The company targets a commercial launch in the first half of 2024, aiming to transform neurosurgery procedures and improve patient outcomes. The OneRF Ablation System is the company's third FDA 510(k)-cleared device, expanding its line of electrode technology to address patients requiring diagnostic brain mapping procedures as well as RF ablation using the same sEEG electrode. The current brain ablation market is estimated to be at least $100M worldwide and growing rapidly, with the potential to grow multifold based on large addressable patient populations with unmet clinical needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.94%
Tags
clinical trial
News

NeuroOne® to Report Fourth Quarter and Fiscal Year 2023 Financial Results and Provide Corporate Update on December 14

Rhea-AI Summary
NeuroOne Medical Technologies Corporation (NMTC) to discuss Q4 and fiscal year 2023 financial results and corporate update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.26%
Tags
conferences earnings
-
News

NeuroOne® Announces Patent Allowance for Drug Delivery Utilizing a Novel Neural Probe

Rhea-AI Summary
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) announced that the USPTO issued a Notice of Allowance for a patent covering novel electrodes that can deliver a treatment agent to a patient's brain. The company's patent portfolio includes two other allowed patent applications, one issued U.S. patent, eight pending U.S. applications, and several foreign applications covering thin-film electrode technologies. CEO Dave Rosa highlighted the importance of these allowances in advancing the company's efforts to partner with biopharma companies for combination devices.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
none
-
News

NeuroOne® Appoints Medtech Executive Christopher R. Volker as Chief Operating Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) announced the appointment of Christopher R. Volker as Chief Operating Officer, strengthening the management team. Mr. Volker brings extensive experience from Abbott Laboratories and Cardiovascular Systems, Inc., with a focus on international commercial expansion and therapy development. The company also disclosed an equity award under the Inducement Plan for Mr. Volker.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
management
News

NeuroOne® Provides Progress Update on FDA 510(k) Submission for OneRF™ Ablation System

Rhea-AI Summary
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) responded to FDA questions on its OneRF Ablation System, expecting feedback in 30 days. The system offers transformative improvement in neurosurgery, combining diagnostic and therapeutic capabilities with potential cost reduction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.49%
Tags
none
-
News

NeuroOne® to Present at the ThinkEquity Conference on October 19, 2023

Rhea-AI Summary
NeuroOne Medical Technologies to present at ThinkEquity Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
conferences
-
News

NeuroOne® to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Rhea-AI Summary
NeuroOne to present at H.C. Wainwright Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.01%
Tags
conferences
News

NeuroOne® Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.76%
Tags
earnings

FAQ

What is the current stock price of NeuroOne Medical Technologies Corporation (NMTC)?

The current stock price of NeuroOne Medical Technologies Corporation (NMTC) is $0.6998 as of November 21, 2024.

What is the market cap of NeuroOne Medical Technologies Corporation (NMTC)?

The market cap of NeuroOne Medical Technologies Corporation (NMTC) is approximately 22.2M.

What does NeuroOne Medical Technologies Corporation focus on?

NeuroOne focuses on developing and commercializing thin-film electrode technology for cEEG and sEEG recording, brain stimulation, and ablation solutions.

Where is NeuroOne Medical Technologies Corporation based?

The company is based in Eden Prairie, Minnesota.

What disorders does NeuroOne's technology address?

Their technology addresses brain-related disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors.

What is the Evo® sEEG system?

The Evo® sEEG system is an FDA-cleared thin-film sEEG-guided RF system that can record electrical activity and ablate nervous tissue with temperature control.

What are some of NeuroOne's current projects?

Current projects include the Drug Delivery Program and the OneRF™ Ablation System, among others.

How can I contact NeuroOne Medical Technologies Corporation?

You can contact them at 800-631-4030 or email ir@nmtc1.com.

What recent financial updates has NeuroOne provided?

In the second quarter of fiscal year 2024, NeuroOne reported progress in the OneRF™ Ablation System and Spinal Cord Stimulation Program.

What type of medical technology does NeuroOne specialize in?

NeuroOne specializes in neuromodulation technology, particularly thin-film electrode technology for cEEG and sEEG recording, brain stimulation, and ablation.

What is the significance of the FDA clearance for NeuroOne's technology?

The FDA clearance for the Evo® sEEG system signifies the approval and safety of the technology for medical use, affirming its efficacy in recording electrical activity and ablating nervous tissue.

Where can I find more detailed financial results and updates about NeuroOne?

Detailed financial results and updates can be accessed through quarterly conference calls and webcasts organized by the company.

Stock NMTC logo
NeuroOne Medical Technologies Corporation

Nasdaq:NMTC

NMTC Rankings

#5244 Ranked by Market Cap
N/A Ranked by Dividends

NMTC Stock Data

22.18M
27.38M
10.19%
19.46%
0.4%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
EDEN PRAIRIE